
    
      This was a Phase 2, dose finding study designed to evaluate peginesatide treatment of
      participants with CKD not on ESA treatment. The objective was to determine the range of doses
      of peginesatide administered subcutaneously once every 4 weeks (Q4W) that increased and
      maintained hemoglobin at 11 to 13 g/dL.
    
  